Is AMGN a buy in 2026? As the global biotechnology sector undergoes a massive wave of transformation driven by the obesity drug gold rush and rare disease innovation, Amgen Inc. (NASDAQ: AMGN) stands at a highly critical crossroads. For decades, the Thousand Oaks, California-based pharmaceutical pioneer was categorized by Wall Street as a reliable, defensive income play - valued for its steady cash flows and high dividend yield, but lacking the rapid growth catalysts found in tech or smaller biotech peers. Today, however, that legacy narrative is being completely rewritten.

With the company's recent Q1 2026 financial release posting solid top-line gains, and its late-stage pipeline capturing the market's attention, the central question for Wall Street remains: Is AMGN a premium value opportunity or is the stock priced for perfection? In this comprehensive, deep-dive analysis, we will unpack the fundamentals of AMGN, explore the massive market potential of its investigational obesity drug MariTide, evaluate its post-acquisition integration of Horizon Therapeutics, and assess whether its current valuation represents a rare buying opportunity.

The Financial Foundation: AMGN's Core Commercial Growth

To understand the investment thesis for AMGN, we must first look at how the company manages its legacy portfolio. Unlike early-stage biotech companies that rely purely on clinical trial optimism, Amgen operates a highly lucrative, multi-billion-dollar commercial engine. In its first-quarter 2026 financial results reported on April 30, 2026, Amgen delivered total revenues of $8.6 billion, representing a robust 6% year-over-year increase that surpassed consensus Wall Street estimates of $8.5 billion.

This growth is particularly impressive when considering that Amgen is in the middle of a massive transitional phase. Historically, Amgen has proven itself to be highly resilient in the face of patent expirations. The company previously survived the biosimilar erosion of major blockbuster therapeutics like Epogen, Aranesp, and Neulasta. By developing its own highly successful biosimilar business unit (Amgen Biosimilars) and pivoting aggressively toward next-generation biologics, management demonstrated its unique capital allocation capabilities.

In 2026, the company's core commercial lineup is firing on all cylinders, driven by a robust 9% increase in product volumes which helped offset minor pricing headwinds. Standout performers in the commercial lineup include:

• Repatha (evolocumab): Amgen's PCSK9 inhibitor has matured into an undisputed blockbuster. In Q1 2026, Repatha generated $876 million in sales, representing a whopping 34% year-over-year increase. Its long-term viability was further cemented in March 2026 by groundbreaking clinical data showing that Repatha reduces the risk of major cardiovascular events by 31% in high-risk patients without previous atherosclerosis.
• Tezspire (tezepelumab-ekko): Developed in collaboration with AstraZeneca, this severe asthma treatment continues its explosive trajectory, consistently delivering double-digit year-over-year growth and gaining significant market share.
• Evenity (romosozumab-aqqg): This osteoporosis therapy continues to show rapid global adoption, posting substantial double-digit growth and securing its position as a major pillar of Amgen's general medicine segment.

Amgen's diversified revenue stream gave management the confidence to project full-year 2026 revenues between $37.1 billion and $38.5 billion. On a non-GAAP basis, full-year EPS is expected to fall between $21.70 and $23.10. With 16 brands achieving double-digit volume growth in Q1 2026, the base business provides an incredibly stable floor for AMGN investors, providing the massive cash flows needed to fund research and development.

The MariTide Catalyst: Redefining Obesity and Dosing Frequency

While the core business provides stability, the single biggest catalyst for AMGN's valuation is its clinical pipeline in the cardiometabolic and obesity sectors. All eyes on Wall Street are fixed on MariTide (maridebart cafraglutide, formerly AMG 133).

The global obesity market is projected to reach $100 billion by 2030, currently dominated by Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide). However, these first-generation GLP-1 drugs require weekly self-injections and often suffer from high patient discontinuation rates due to side effects, pricing, or needle fatigue. Furthermore, clinical evidence suggests that patients who stop taking weekly GLP-1s quickly regain the majority of the weight they lost.

MariTide represents a massive scientific leap forward. It is a first-in-class antibody-peptide conjugate (APC). Structurally, it consists of a fully human monoclonal antibody that blocks the glucose-dependent insulinotropic polypeptide receptor (GIPR antagonism) conjugated to two GLP-1 receptor agonist peptides. While Eli Lilly's tirzepatide activates both the GLP-1 and GIP receptors, Amgen's deCODE Genetics unit in Iceland discovered that blocking the GIP receptor - rather than activating it - while simultaneously activating the GLP-1 pathway yields powerful, highly durable weight reduction.

This molecular engineering gives MariTide two massive advantages that could allow Amgen to capture a significant share of the obesity market:

1. Infrequent Dosing (Monthly or Less): MariTide's antibody backbone gives it an extremely long plasma half-life of approximately 21 days - about three times longer than approved weekly GLP-1 therapies. Phase 2 clinical data demonstrated that once-monthly dosing resulted in a highly competitive 15% to 20% weight loss at 52 weeks. Amgen is actively testing monthly, every-eight-week, and even quarterly (four times a year) dosing regimens.
2. Durability of Weight Loss: Perhaps the most remarkable finding from early-stage clinical trials is that patients who discontinued MariTide maintained an 11.2% weight reduction for up to 150 days (five months) after their last dose without rapid weight regain. In contrast, patients who stop taking Wegovy or Zepbound typically experience rapid weight rebound.

In early 2026, Amgen initiated multiple trials in its Phase 3 MARITIME program. Alongside MARITIME-1 (chronic weight management in obesity or overweight) and MARITIME-2 (obesity with Type 2 diabetes), the company has introduced the highly strategic MARITIME-SWITCH study. This 300-patient trial is specifically designed to evaluate transitioning patients who are currently taking weekly semaglutide or tirzepatide directly to an every-eight-week or quarterly dose of MariTide. If successful, this trial will provide a powerful commercial blueprint for physicians to switch patients from weekly treatments to Amgen's highly convenient monthly/quarterly regimen.

Additionally, Amgen announced a crucial refinement in Q1 2026: a new 3-step dose escalation protocol studied in Phase 1 physiology trials has shown to dramatically reduce gastrointestinal side effects (nausea and vomiting) compared to the previous 2-step protocol. This ensures that when Phase 3 data is released, MariTide could feature an industry-leading tolerability profile.

Rare Disease and the Horizon Therapeutics Integration

Beyond obesity, AMGN has significantly diversified its portfolio through its acquisition of Horizon Therapeutics. This landmark $27.8 billion deal was completed in October 2023 after surviving intense FTC scrutiny, marking a major turning point for Amgen's footprint in the high-margin rare disease sector.

By mid-2026, the Horizon integration has matured and is yielding significant clinical and commercial fruits. The rare disease segment generated over $5.2 billion in FY2025 and continues to grow at a mid-double-digit clip. The primary pillars of this acquisition include:

• Tepezza (teprotumumab-trbw): The only FDA-approved treatment for Thyroid Eye Disease (TED). In April 2026, Amgen announced positive topline results from its Phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza. Historically, Tepezza required time-consuming intravenous infusions; a subcutaneous injection option dramatically simplifies administration, improves patient compliance, and lowers clinical overhead, paving the way for expanded market penetration.
• Krystexxa (pegloticase): A highly effective biologic for uncontrolled gout that has shown sustained double-digit growth under Amgen's global commercial umbrella.
• Uplizna (inebilizumab-cdon): Used for neuromyelitis optica spectrum disorder (NMOSD), Uplizna received European Commission approval in February 2026 for generalized Myasthenia Gravis (gMG), significantly expanding its addressable global patient population.

By layering Horizon's high-margin rare disease therapies on top of its world-class biologics manufacturing and global commercial scale, Amgen has successfully mitigated the slower growth trends of its mature product lines.

Headwinds, Patent Cliffs, and Key Risks

Despite its strong growth engines, AMGN is not without risks. Investors must weigh these key challenges:

• The Prolia and Xgeva Patent Cliff: Amgen's blockbuster denosumab formulations (Prolia and Xgeva), which treat osteoporosis and bone metastases, face loss of exclusivity and biosimilar competition over the next few years. These products represent a significant portion of current revenue, and their erosion will require massive offsets from Repatha and the emerging rare disease pipeline.
• Regulatory Uncertainty: In its Q1 2026 update, Amgen revealed that the US FDA has proposed to withdraw the approval of Tavneos (avacopan) for severe active ANCA-associated vasculitis. While Tavneos represents a smaller slice of overall revenues, this regulatory friction highlights the ongoing regulatory risks associated with biotech investing.
• Oncology Adjustments: Amgen announced the discontinuation of AMG 193, its MTA-cooperative PRMT5 inhibitor in oncology, showing that clinical execution is always subject to pipeline attrition.

AMGN Stock Valuation: A Massive Discount to Intrinsic Value?

Let's look at the numbers. Trading at approximately $334 to $336 per share in late May 2026, AMGN is valued at a forward Price-to-Earnings (P/E) ratio of just 15.1x. This is a substantial discount to the S&P 500 average and significantly cheaper than mega-cap pharmaceutical peers like Eli Lilly or Novo Nordisk.

Furthermore, a conservative Two-Stage Discounted Cash Flow (DCF) model reveals a massive valuation gap. With Amgen's current free cash flow at approximately $9.1 billion, and analysts projecting FCF to rise to $16.7 billion by 2030 (driven by MariTide's launch and rare disease expansion), the intrinsic value of AMGN is estimated at roughly $655 per share. Even with moderate terminal growth assumptions, the stock currently trades at an estimated 48% discount to its cash flow potential.

For income-focused investors, AMGN remains an exceptional dividend growth opportunity. The Board of Directors declared a $2.52 per share dividend for the second quarter of 2026, resulting in an annualized dividend of $10.08 and a forward yield of approximately 3.0%. Combine this yield with Amgen's commitment to keep share repurchases under $3 billion in 2026, and the stock offers highly defensive capital return metrics.

Conclusion

In summary, Amgen (NASDAQ: AMGN) is undergoing a major evolution. While the impending patent cliff for Prolia and Xgeva has kept traditional valuation multiples compressed, the commercial momentum of Repatha, the successful integration of Horizon's high-margin rare disease portfolio, and the revolutionary monthly/quarterly potential of MariTide make AMGN an outstanding value and growth play. At a forward P/E of 15.1x and a safe 3% dividend yield, AMGN represents a rare and highly attractive risk-reward profile for long-term biotech investors.

Frequently Asked Questions (FAQ)

What is the current AMGN price target for 2026?

The consensus twelve-month price target for AMGN among Wall Street analysts is approximately $352 to $355, representing a steady upside. The highest analyst estimates reach up to $427, while the most conservative bear cases sit at around $200.

What makes Amgen's MariTide different from Wegovy and Zepbound?

Unlike Wegovy (which activates GLP-1) and Zepbound (which activates both GLP-1 and GIP), MariTide is an antibody-peptide conjugate that blocks GIP receptors while activating GLP-1. This unique mechanism allows for once-monthly or even quarterly dosing, and early trial data suggests patients maintain their weight loss much longer after stopping treatment compared to daily or weekly competitors.

How has the Horizon Therapeutics acquisition impacted Amgen's financial health?

The acquisition of Horizon Therapeutics has diversified Amgen's revenue into the highly profitable rare disease sector. By 2026, these products (Tepezza, Krystexxa, and Uplizna) are generating over $5.2 billion in annual sales and growing rapidly, which successfully offsets the patent expirations in Amgen's legacy general medicine business.

What are the major risks facing Amgen (AMGN) stock?

The primary risks include biosimilar competition for legacy blockbusters Prolia and Xgeva, potential clinical or regulatory setbacks for MariTide during its ongoing Phase 3 MARITIME trials, and regulatory challenges such as the FDA's proposed withdrawal of Tavneos.

Is Amgen a reliable dividend stock?

Yes. Amgen is a highly reliable dividend payer with a yield of approximately 3.0% as of mid-2026. The company recently declared a Q2 2026 dividend of $2.52 per share, reflecting a strong commitment to returning capital to shareholders.